• Universal Health Care & Suppliers

  • Universal Health Care and Suppliers

  • Authorized distributor: Ajanta pharma

  • 118/119, 1st Floor, Hariom Plaza, Behind Omkareshwar Mandir, Opp. National Park, M.G.Road, Borivali(East).
    Mumbai - 400 066. India

  •  +91 9819 868 868
  •  +91 22-65336533
  •  +91 22-28931222
  •   info@universalhealthindia.com

Bimat eye drop

Bimatoprost Ophthalmic solution 0.03% w/v.

Each ml contains::
Bimatoprost                            0.3 mg
Benzalkonium Chloride IP   0.005% w/v
Sterile aqueous vehicle         q.s.


Mechanism of Action (MOA):

Bimatoprost is a synthetic structure which is comparable to prostaglandin with ocular hypotensive activity. It selectively imitates the effects of naturally happening substances Pros amides. Bimatoprost is believed to lower intraocular pressure (I0P) in humans by expanding outflow of aqueous humor through both the uveoscleral routes and trabecular meshwork. Elevated I0P presents a major risk factor for glaucomatous field loss. The higher the level of I0P, the greater the like hood of visual field loss and optic nerve damage.
Bimatoprost is contraindicated in patients with hypersensitivity to Bimatoprost or any other ingredient in this product.
There has been no appreciable systemic drug accumulation over time.
Bimat 0.03% is indicated for the reduction of raised intraocular pressure in patients with open angle glaucoma or ocular hypertension who are inflexible of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target I0P determined after multiple measurements over time) to another intraocular pressure lowering medication.
Bimatoprost causes changes to pigmented tissues. These reports include growth of eyelashes and increased pigmentation of the iris and eyelid. These changes may be permanent.
Patients may develop increased brown pigmentation of the iris. For several months to years
This change may not be noticeable. Generally the brown pigmentation around the pupil is expected to spread concentrically towards the edge in affected eyes, but the entire iris may also have more brownish tint. Until more information about increased brown pigmentation is present, patients should be inspected regularly depending on the clinical situation. Treatment may be stopped if increased pigmentation ensues. The rise in brown iris pigment is not expected to progress further upon the end of the treatment, but the concomitant color change may be permanent.
Neither nevi nor freckles of the iris are expected to be affected by treatment.